5 Projects | 1 Researchers | $3,263,017 Invested
2021
Life Biosciences
Sharon Rosenzweig-Lipson, PhD
Effects of Chaperone-Mediated Autophagy in Alzheimer's Disease
2019
AgeneBio Inc
Sharon Rosenzweig-Lipson, PhD
In Vivo Characterization of a GABA-A alpha-5 Positive Allosteric Modulator
2016
AgeneBio Inc
Sharon Rosenzweig-Lipson, PhD
Accelerating Manufacture of Clinical Supplies for Initiation of Patient Enrollment in the HOPE4MCI Phase 3 Trial (AgeneBio, AGB101)
2016
AgeneBio Inc
Sharon Rosenzweig-Lipson, PhD
GABA-A alpha-5 Positive Allosteric Modulators for the treatment of aMCI due to AD.
2014
AgeneBio Inc
Sharon Rosenzweig-Lipson, PhD
Accelerating a Phase III MCI Clinical Trial with Phase I Evaluation of a Novel Extended-Release Levetiracetam Formulation